NASDAQ:INSM - Insmed Stock Price, Forecast & News

Insmed trades on the NASDAQ under the ticker symbol "INSM."

Insmed Incorporated (NASDAQ:INSM) posted its earnings results on Tuesday, February, 25th. The biopharmaceutical company reported ($0.59) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.58) by $0.01. The biopharmaceutical company earned $45.70 million during the quarter, compared to the consensus estimate of $45.06 million. Insmed had a negative return on equity of 94.35% and a negative net margin of 186.37%. Insmed's revenue for the quarter was up 366.3% compared to the same quarter last year. View Insmed's Earnings History.

Insmed is scheduled to release their next quarterly earnings announcement on Tuesday, May 5th 2020. View Earnings Estimates for Insmed.

7 Wall Street analysts have issued 12 month price targets for Insmed's stock. Their forecasts range from $20.00 to $56.00. On average, they anticipate Insmed's share price to reach $43.43 in the next twelve months. This suggests a possible upside of 80.3% from the stock's current price. View Analyst Price Targets for Insmed.

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Insmed in the last year. There are currently 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Insmed.

Headlines about INSM stock have trended very negative on Friday, according to InfoTrie Sentiment. InfoTrie identifies negative and positive media coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Insmed earned a coverage optimism score of -3.0 on InfoTrie's scale. They also gave media headlines about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the company's share price in the immediate future. View News Stories for Insmed.

Insmed saw a decrease in short interest in the month of January. As of January 31st, there was short interest totalling 12,940,000 shares, a decrease of 8.6% from the January 15th total of 14,150,000 shares. Based on an average trading volume of 946,400 shares, the short-interest ratio is presently 13.7 days. Approximately 15.3% of the shares of the company are sold short. View Insmed's Current Options Chain.

Some companies that are related to Insmed include Perrigo (PRGO), Sarepta Therapeutics (SRPT), Bausch Health Companies (BHC), Catalent (CTLT), Ionis Pharmaceuticals (IONS), Dr.Reddy's Laboratories (RDY), The Medicines (MDCO), Jazz Pharmaceuticals (JAZZ), Horizon Therapeutics (HZNP), Ascendis Pharma A/S (ASND), ACADIA Pharmaceuticals (ACAD), Reata Pharmaceuticals (RETA), Amarin (AMRN), United Therapeutics (UTHR) and BridgeBio Pharma (BBIO).

Based on aggregate information from My MarketBeat watchlists, some companies that other Insmed investors own include AbbVie (ABBV), Gilead Sciences (GILD), Geron (GERN), Intercept Pharmaceuticals (ICPT), Incyte (INCY), Capstone Turbine (CPST), NVIDIA (NVDA), Alibaba Group (BABA), Bausch Health Companies (BHC) and CHIMERA INVT CO/SH NEW (CIM).

Insmed's stock is owned by many different of retail and institutional investors. Top institutional investors include FMR LLC (15.00%), Janus Henderson Group PLC (13.06%), Palo Alto Investors LP (7.67%), Eagle Asset Management Inc. (1.69%), Geode Capital Management LLC (1.36%) and Fairmount Funds Management LLC (1.11%). Company insiders that own Insmed stock include Alfred Altomari, Donald J Hayden Jr, John Goll, Melvin Md Sharoky, Orlov S Nicole Schaeffer, Roger Adsett, Steinar J Engelsen and William Lewis. View Institutional Ownership Trends for Insmed.

INSM stock was sold by a variety of institutional investors in the last quarter, including Janus Henderson Group PLC, Bank of America Corp DE, Point72 Asset Management L.P., Marshall Wace LLP, Palo Alto Investors LP, Emerald Advisers LLC, Emerald Mutual Fund Advisers Trust and Rafferty Asset Management LLC. Company insiders that have sold Insmed company stock in the last year include Donald J Hayden Jr, John Goll, Orlov S Nicole Schaeffer and William Lewis. View Insider Buying and Selling for Insmed.

INSM stock was acquired by a variety of institutional investors in the last quarter, including Fairmount Funds Management LLC, FMR LLC, Goldman Sachs Group Inc., Lord Abbett & CO. LLC, AXA, California Public Employees Retirement System, Geode Capital Management LLC and Franklin Resources Inc.. Company insiders that have bought Insmed stock in the last two years include Melvin Md Sharoky, Roger Adsett, Steinar J Engelsen and William Lewis. View Insider Buying and Selling for Insmed.

Shares of INSM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of INSM stock can currently be purchased for approximately $24.09.

Insmed has a market capitalization of $2.16 billion and generates $136.47 million in revenue each year. The biopharmaceutical company earns $-324,280,000.00 in net income (profit) each year or ($3.01) on an earnings per share basis. Insmed employs 373 workers across the globe.View Additional Information About Insmed.

The official website for Insmed is http://www.insmed.com/.

Insmed's mailing address is 10 Finderne Avenue Building 10, Bridgewater NJ, 08807. The biopharmaceutical company can be reached via phone at 908-977-9900 or via email at [email protected]